ClariTrial | Search Clinical Trials

Explore/Nurix Therapeutics

Status

Phase

10 results for “Nurix Therapeutics”

Terminated

A Study of DeTIL-0255 in Adults With Advanced Malignancies

Phase 1Platinum-resistant Ovarian CancerEndometrial CancerCervical Cancer

Drug Product De-TIL-0255

Nurix Therapeutics, Inc.5 participants4 sites · United StatesCompletes May 2023

Compare CT.gov Full analysis →

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer

NX-1607Paclitaxel

Nurix Therapeutics, Inc.345 participants17 sites · United States, United KingdomCompletes Aug 2026

Compare CT.gov Full analysis →

Completed

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

Phase 1Healthy Volunteers

IPMatching Placebo

Nurix Therapeutics, Inc.32 participants1 site · United StatesCompletes Oct 2024

Compare CT.gov Full analysis →

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Diffuse Large B Cell Lymphoma (DLBCL)

NX-5948

Nurix Therapeutics, Inc.572 participants62 sites · United States, France, ItalyCompletes Jan 2027

Compare CT.gov Full analysis →

Not Yet Recruiting

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Phase 1Phase 2B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

NX-5948venetoclaxrituximab+1 more

Nurix Therapeutics, Inc.150 participantsCompletes May 2033

Compare CT.gov Full analysis →

Recruiting

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

Phase 1Healthy Volunteer

NX-5948Esomeprazole

Nurix Therapeutics, Inc.18 participants1 site · United StatesCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Phase 2Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

NX-5948

Nurix Therapeutics, Inc.100 participants32 sites · United States, France, ItalyCompletes Jan 2028

Compare CT.gov Full analysis →

Completed

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

Phase 1Healthy Volunteer

NX-5948

Nurix Therapeutics, Inc.8 participants1 site · United StatesCompletes Nov 2024

Compare CT.gov Full analysis →

Not Yet Recruiting

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Phase 3B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

NX-5948Pirtobrutinib

Nurix Therapeutics, Inc.620 participantsCompletes Oct 2029

Compare CT.gov Full analysis →

Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)

NX-2127

Nurix Therapeutics, Inc.248 participants16 sites · United StatesCompletes May 2026

Compare CT.gov Full analysis →

1–10 of 10

Explore/Nurix Therapeutics

Status

Phase

10 results for “Nurix Therapeutics”

Terminated

A Study of DeTIL-0255 in Adults With Advanced Malignancies

Phase 1Platinum-resistant Ovarian CancerEndometrial CancerCervical Cancer

Drug Product De-TIL-0255

Nurix Therapeutics, Inc.5 participants4 sites · United StatesCompletes May 2023

Compare CT.gov Full analysis →

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer

NX-1607Paclitaxel

Nurix Therapeutics, Inc.345 participants17 sites · United States, United KingdomCompletes Aug 2026

Compare CT.gov Full analysis →

Completed

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

Phase 1Healthy Volunteers

IPMatching Placebo

Nurix Therapeutics, Inc.32 participants1 site · United StatesCompletes Oct 2024

Compare CT.gov Full analysis →

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Diffuse Large B Cell Lymphoma (DLBCL)

NX-5948

Nurix Therapeutics, Inc.572 participants62 sites · United States, France, ItalyCompletes Jan 2027

Compare CT.gov Full analysis →

Not Yet Recruiting

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Phase 1Phase 2B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

NX-5948venetoclaxrituximab+1 more

Nurix Therapeutics, Inc.150 participantsCompletes May 2033

Compare CT.gov Full analysis →

Recruiting

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

Phase 1Healthy Volunteer

NX-5948Esomeprazole

Nurix Therapeutics, Inc.18 participants1 site · United StatesCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Phase 2Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

NX-5948

Nurix Therapeutics, Inc.100 participants32 sites · United States, France, ItalyCompletes Jan 2028

Compare CT.gov Full analysis →

Completed

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

Phase 1Healthy Volunteer

NX-5948

Nurix Therapeutics, Inc.8 participants1 site · United StatesCompletes Nov 2024

Compare CT.gov Full analysis →

Not Yet Recruiting

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Phase 3B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

NX-5948Pirtobrutinib

Nurix Therapeutics, Inc.620 participantsCompletes Oct 2029

Compare CT.gov Full analysis →

Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)

NX-2127

Nurix Therapeutics, Inc.248 participants16 sites · United StatesCompletes May 2026

Compare CT.gov Full analysis →

1–10 of 10